Pathogenetic basis of modern approaches to the therapy of sleep disorders in the clinic of depression
Raspopova N.I.
2024Media Sphera Publishing Group
Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova
2024#124Issue 469 - 74 pp.
Epidemiological studies indicate that about 35% of the world’s population periodically suffer from insomnia. Many authors in their studies note sleep disturbances in the clinic of both somatic and mental disorders, often considering sleep disturbances as one of the predictors of these diseases. In psychiatric practice, sleep disorders are most often described in the clinic of depression, which is determined by the general pathophysiological mechanisms of their development due to disruption of the activity of the main neurotransmitter systems of the brain. The results of clinical studies show that the drug of choice in the treatment of sleep disorders in the depression clinic is the antidepressant Mirtazapine, which has a unique profile of pharmacological activity. According to international recommendations, Mirtazapine is a first-line drug in the treatment of anxiety and depressive disorders with sleep disorders and sexual dysfunction caused by taking other antidepressants.
antidepressants , depression , Mirtazapine , sleep
Text of the article Перейти на текст статьи
Kazakhstan-Russian Medical University, Almaty, Kazakhstan
Kazakhstan-Russian Medical University
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026